Our data here show that FGFR1 signaling contributes to the suppression of CDKN1C via epigenetic regulation in MCL and may be targeted in ibrutinib-resistant patients, but this hypothesis requires further validation. Here, CDKN1C is linked to mantle cell lymphoma.